🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Long term results of Low dose Nivolumab study ⁦Vanita Noronha, MBBS MD DM⁩ ⁦Nandini Menon⁩ ⁦Dr Amol Akhade⁩ ⁦Amol Patel⁩ ⁦Sewanti Limaye 🇮🇳🇺🇸⁩ ⁦ASCO⁩. Tripling of survival at 2.5 years.

🚨 PM Modi shared a funny but powerful line from a Congress leader : “India’s problems can be solved if POLITICIANS learn to say ‘No’ and BUREAUCRATS learn to say ‘Yes’.” He added⚡️, “The truth is — politicians never say NO, and officers never say YES”😄🎯

Medical Oncologist: Breast cancer, Lung cancer, Lymphoma, Prostate cancer etc.. running clinics simultaneously

"About a quarter of the approximately 13,600 drug-target pairs in the current preclinical and clinical R&D pipeline are concentrated around just 38 unique biological targets." - LEK. This is astonishing & a huge misappropriation of risk by investors. lek.com/insights/hea/u…

ctDNA-guided adj CTx escalation in stage III CRC #ASCO25 🔎Primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial 👉mRFS 29 vs 36 mo 👉CTx escalation does not improve outcome 🧐 ctDNA very helpful to understand risk groups, but we need better

Who takes care of patients when most of us are at ASCO ?

TDxD replaced the Ramucirumab Paclitaxel in Her2neu + advanced gastric cancer. nejm.org/doi/full/10.10…

Come to the Poster#279 and see the state-of-the-art from published low dose immuntherapy use worldwide 💥Efficacy as monotherapy, reaching meaningful RRs as in the pioneer phase 1 Pembro/Nivo ‼️Awaiting for upcoming no-inferiority studies A pleasure to have work alongside such

Zindagi jeena bahot saral hai lekin usko mushkil banana usse bhi zyaada saral hai 😁

Honored to have presented 1 oral abstract and presented/co-authored 4 posters at #ASCO25 —an incredible experience representing the impactful research led by Mayo Clinic Comprehensive Cancer Center . Grateful to my collaborators for their partnership and support.

Few more glimpses of Special Joint State Representatives and Additional/Deputy Directors General (JS R&A/D) Conference of NCC held at Bhopal on June 3, 2025. #NCCYouthEmpowerment Rajnath Singh Sanjay Seth Ministry of Defence, Government of India ADG PI - INDIAN ARMY Indian Air Force SpokespersonNavy

A cheaper way to identify HRD positive tumors that might benefit from PARPi+Bev maintenance in ovarian cancer? In the PAOLA-1/ENGOT-ov25 trial (n=519), BRCA1/RAD51C methylation testing showed PFS & OS benefit with bevacizumab+olaparib maintenance. ✅ Identified ~85% of HRD+

Yes, it is amazing way to care for citizens. Universal Health and Education.

Namma Chennai, एक से मन नहीं भरा, दो कॉफ़ी पिया

Dr Amol Akhade Non-inferiority trial is a mirage! You can’t imagine the budget required for such studies. Wrote a phase IIb for RCC, budget was almost 3 Crs. Sometime back, I suggested the new concept of “Prospective propensity match study”. But, हम लकीर के फ़क़ीर है, जब तक हार्वर्ड वाले और

Many of us ask the truth by the non-inferiority trials. Always question the existence of such tyranny. Low dose immunotherapy is largely accepted by many of us. For those who want that in NCCN, they can very well wait and keep waiting….. thelancet.com/journals/lanon…

What holds India back from implementing this?

This is the condition of free houses given to slum dwellers in PM Awas Yojana. India does not deserve a good PM like Modi😢💔